Publications by authors named "Xenia Radu"
Article Synopsis
- Inflammatory bowel disease (IBD) leads to significant social and economic challenges, prompting an analysis of the budget impact of using a new subcutaneous formulation of vedolizumab for maintaining ulcerative colitis (UC) treatment in France.
- A decision-analytic model was created to compare the costs of including vedolizumab SC as maintenance therapy against existing treatment options, predicting total drug, medical, and indirect costs over a five-year period.
- Results showed that incorporating vedolizumab SC could save over €59 million for biologic-naïve patients and nearly €22 million for those already on biologics, indicating strong financial benefits for French health plans.
Article Synopsis
- Ulcerative colitis is a common condition in Canada, necessitating the exploration of affordable treatment options; the study evaluates the cost-effectiveness of the newly approved subcutaneous vedolizumab compared to various other therapies from a Canadian healthcare payer's perspective.* -
- A decision tree/Markov model was used to analyze costs, quality-adjusted life-years (QALYs), and treatment effectiveness for vedolizumab SC against several established therapies, accounting for uncertainties and varying treatment scenarios.* -
- Results indicated that while conventional therapy was the most cost-effective overall, vedolizumab SC was a cost-effective and leading option when compared to other advanced treatments, offering significant savings and achieving the highest QALYs among